These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 12019088)

  • 121. New strategies against drug resistance to herpes simplex virus.
    Jiang YC; Feng H; Lin YC; Guo XR
    Int J Oral Sci; 2016 Mar; 8(1):1-6. PubMed ID: 27025259
    [TBL] [Abstract][Full Text] [Related]  

  • 122. CDK9 inhibitor FIT-039 prevents replication of multiple DNA viruses.
    Yamamoto M; Onogi H; Kii I; Yoshida S; Iida K; Sakai H; Abe M; Tsubota T; Ito N; Hosoya T; Hagiwara M
    J Clin Invest; 2014 Aug; 124(8):3479-88. PubMed ID: 25003190
    [TBL] [Abstract][Full Text] [Related]  

  • 123. Pharmacokinetics-pharmacodynamics of the helicase-primase inhibitor pritelivir following treatment of wild-type or pritelivir-resistant virus infection in a murine herpes simplex virus 1 infection model.
    Biswas S; Sukla S; Goldner T; Field HJ; Kropeit D; Paulsen D; Welbers A; Ruebsamen-Schaeff H; Zimmermann H; Birkmann A
    Antimicrob Agents Chemother; 2014 Jul; 58(7):3843-52. PubMed ID: 24752278
    [TBL] [Abstract][Full Text] [Related]  

  • 124. Effect of ASP2151, a herpesvirus helicase-primase inhibitor, in a guinea pig model of genital herpes.
    Katsumata K; Chono K; Sudo K; Shimizu Y; Kontani T; Suzuki H
    Molecules; 2011 Aug; 16(9):7210-23. PubMed ID: 21869749
    [TBL] [Abstract][Full Text] [Related]  

  • 125. Herpes simplex virus type 1 penetrates the basement membrane in human nasal respiratory mucosa.
    Glorieux S; Bachert C; Favoreel HW; Vandekerckhove AP; Steukers L; Rekecki A; Van den Broeck W; Goossens J; Croubels S; Clayton RF; Nauwynck HJ
    PLoS One; 2011; 6(7):e22160. PubMed ID: 21789229
    [TBL] [Abstract][Full Text] [Related]  

  • 126. Resistance of herpes simplex viruses to nucleoside analogues: mechanisms, prevalence, and management.
    Piret J; Boivin G
    Antimicrob Agents Chemother; 2011 Feb; 55(2):459-72. PubMed ID: 21078929
    [TBL] [Abstract][Full Text] [Related]  

  • 127. Update on new antivirals under development for the treatment of double-stranded DNA virus infections.
    Dropulic LK; Cohen JI
    Clin Pharmacol Ther; 2010 Nov; 88(5):610-9. PubMed ID: 20881959
    [TBL] [Abstract][Full Text] [Related]  

  • 128. Treatment of herpes simplex virus infections in pediatric patients: current status and future needs.
    James SH; Whitley RJ
    Clin Pharmacol Ther; 2010 Nov; 88(5):720-4. PubMed ID: 20881952
    [TBL] [Abstract][Full Text] [Related]  

  • 129. Novel approaches in fighting herpes simplex virus infections.
    Wilson SS; Fakioglu E; Herold BC
    Expert Rev Anti Infect Ther; 2009 Jun; 7(5):559-68. PubMed ID: 19485796
    [TBL] [Abstract][Full Text] [Related]  

  • 130. Antiviral therapy for herpesvirus central nervous system infections: neonatal herpes simplex virus infection, herpes simplex encephalitis, and congenital cytomegalovirus infection.
    James SH; Kimberlin DW; Whitley RJ
    Antiviral Res; 2009 Sep; 83(3):207-13. PubMed ID: 19414035
    [TBL] [Abstract][Full Text] [Related]  

  • 131. Other inhibitors of viral enzymes and functions.
    Zimmermann H; Hewlett G; Rübsamen-Waigmann H
    Handb Exp Pharmacol; 2009; 189(189):155-76. PubMed ID: 19048200
    [TBL] [Abstract][Full Text] [Related]  

  • 132. Differential inhibitory activities and stabilisation of DNA aptamers against the SARS coronavirus helicase.
    Shum KT; Tanner JA
    Chembiochem; 2008 Dec; 9(18):3037-45. PubMed ID: 19031435
    [TBL] [Abstract][Full Text] [Related]  

  • 133. Efficacy of a helicase-primase inhibitor in animal models of ocular herpes simplex virus type 1 infection.
    Kaufman HE; Varnell ED; Gebhardt BM; Thompson HW; Atwal E; Rübsamen-Waigmann H; Kleymann G
    J Ocul Pharmacol Ther; 2008 Feb; 24(1):34-42. PubMed ID: 18201137
    [TBL] [Abstract][Full Text] [Related]  

  • 134. A mutation in the human herpes simplex virus type 1 UL52 zinc finger motif results in defective primase activity but can recruit viral polymerase and support viral replication efficiently.
    Chen Y; Livingston CM; Carrington-Lawrence SD; Bai P; Weller SK
    J Virol; 2007 Aug; 81(16):8742-51. PubMed ID: 17553899
    [TBL] [Abstract][Full Text] [Related]  

  • 135. Understanding helicases as a means of virus control.
    Frick DN; Lam AM
    Curr Pharm Des; 2006; 12(11):1315-38. PubMed ID: 16611118
    [TBL] [Abstract][Full Text] [Related]  

  • 136. Viral and cellular RNA helicases as antiviral targets.
    Kwong AD; Rao BG; Jeang KT
    Nat Rev Drug Discov; 2005 Oct; 4(10):845-53. PubMed ID: 16184083
    [TBL] [Abstract][Full Text] [Related]  

  • 137. Recent highlights in the development of new antiviral drugs.
    De Clercq E
    Curr Opin Microbiol; 2005 Oct; 8(5):552-60. PubMed ID: 16125443
    [TBL] [Abstract][Full Text] [Related]  

  • 138. Mutations in the putative zinc-binding motif of UL52 demonstrate a complex interdependence between the UL5 and UL52 subunits of the human herpes simplex virus type 1 helicase/primase complex.
    Chen Y; Carrington-Lawrence SD; Bai P; Weller SK
    J Virol; 2005 Jul; 79(14):9088-96. PubMed ID: 15994803
    [TBL] [Abstract][Full Text] [Related]  

  • 139. The Epstein-Barr virus replication protein BBLF2/3 provides an origin-tethering function through interaction with the zinc finger DNA binding protein ZBRK1 and the KAP-1 corepressor.
    Liao G; Huang J; Fixman ED; Hayward SD
    J Virol; 2005 Jan; 79(1):245-56. PubMed ID: 15596820
    [TBL] [Abstract][Full Text] [Related]  

  • 140. Antivirals and antiviral strategies.
    De Clercq E
    Nat Rev Microbiol; 2004 Sep; 2(9):704-20. PubMed ID: 15372081
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.